Chen Xi, Wu Meifang
Department of Cardiology, Affiliated Hospital of Putian University, Fujian, China.
Department of Cardiology, Affiliated Hospital of Putian University, Fujian, China.
Am J Med Sci. 2023 Jan;365(1):1-8. doi: 10.1016/j.amjms.2022.07.018. Epub 2022 Sep 6.
Heart failure with reduced ejection fraction (HFrEF) is a prevalent kind of heart failure in which a significant amount of the ejection fraction can be repaired, and left ventricular remodeling and dysfunction can be reversed or even restored completely. However, a considerable number of patients still present clinical signs and biochemical features of incomplete recovery from the pathophysiology of heart failure and are at risk for adverse outcomes such as re-deterioration of systolic function and recurrence of HFrEF. Furthermore, it is revealed from a microscopic perspective that even if partial or complete reverse remodeling occurs, the morphological changes of cardiomyocytes, extracellular matrix deposition, and abnormal transcription and expression of pathological genes still exist. Patients with "recovered ejection fraction" have milder clinical symptoms and better outcomes than those with continued reduction of ejection fraction. Based on the unique characteristics of this subgroup and the existence of many unknowns, the academic community defines it as a new category-heart failure with recovered ejection fraction (HFrecEF). Because there is a shortage of natural history data for this population as well as high-quality clinical and basic research data, it is difficult to accurately evaluate clinical risk and manage this population. This review will present the current understanding of HFrecEF from the limited literature.
射血分数降低的心力衰竭(HFrEF)是一种常见的心力衰竭类型,其中相当一部分射血分数可以得到修复,左心室重构和功能障碍可以得到逆转甚至完全恢复。然而,仍有相当数量的患者表现出心力衰竭病理生理学未完全恢复的临床体征和生化特征,并且面临不良后果的风险,如收缩功能再次恶化和HFrEF复发。此外,从微观角度来看,即使发生了部分或完全的逆向重构,心肌细胞的形态变化、细胞外基质沉积以及病理基因的异常转录和表达仍然存在。“射血分数恢复”的患者比射血分数持续降低的患者临床症状更轻,预后更好。基于该亚组的独特特征以及存在许多未知因素,学术界将其定义为一种新的类型——射血分数恢复的心力衰竭(HFrecEF)。由于该人群缺乏自然史数据以及高质量的临床和基础研究数据,因此难以准确评估临床风险并管理该人群。本综述将根据有限的文献介绍目前对HFrecEF的认识。